Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Following Second Positive Phase 3 Study (PATHFNDR-2), Paltusotine NDA Submission in Acromegaly Expected in 2H 2024 Following Positive Phase 2 Data, Plan to Initiate Paltusotine Phase 3 Study in Carcinoid Syndrome by End of 2024 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024. “Building on the positive momentum from the first PATHFNDR readout in 2023, Crinetics began 2024 with continued strong performance. Our lead investigational compound, paltusotine, delivered positive data from two consecutive late-stage clinical trials in acromegaly and carcinoid syndrome. With our pivotal PATHFNDR Phase 3 program in acromegaly now complete, w
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three years [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
CRNX
Earnings
- 5/9/24 - Miss
CRNX
Sec Filings
- 5/14/24 - Form 4
- 5/10/24 - Form 4
- 5/10/24 - Form 144
- CRNX's page on the SEC website